All In Biotech

Drug Trial Radar · NCT02725060

Autoimmune Basis for Postural Tachycardia Syndrome

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

58

Planned (sponsor's estimate)

Start

Feb 2016

Primary completion

Feb 2027

Study completion Jun 2027

Sponsor

Lead sponsor
Vanderbilt University Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Oklahoma
First posted
Mar 31, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to see if some people with postural tachycardia syndrome (POTS) have higher levels of immune proteins (autoantibodies) directed against receptors of the autonomic nervous system, and if these autoantibodies make a difference in their POTS symptoms. The investigators also want to see if the levels of these autoantibodies stay the same over time.

Conditions

  • Postural Orthostatic Tachycardia Syndrome
  • Postural Tachycardia Syndrome
  • Tachycardia
  • Arrhythmias, Cardiac
  • Autonomic Nervous System Diseases
  • Orthostatic Intolerance
  • Cardiovascular Diseases
  • Primary Dysautonomias

Interventions

  • phenylephrineDrug

    Phenylephrine is a selective α1-adrenergic receptor agonist. It will be given in IV bolus injections starting from 12.5 ug. Incremental doses will be given every \~3 min up to 800 ug or until systolic blood pressure increases by 25 mmHg

  • isoproterenolDrug

    Isoproterenol is non-selective beta-adrenergic agonist. It will be given in IV bolus injections starting from 0.025 ug. Incremental doses will be given every \~3 min until heart rate increases by 25 bpm. This intervention is optional.

  • 25 micro-Ci of radiationRadiation

    Using injection of iodinated I-131 tagged human serum albumin nominally 25 micro-Ci of radiation, blood samples are drawn before and 30 minutes after injection.

  • Posture study with blood samplesProcedure

    Blood pressure and heart rate will be measured while supine and then while standing for up to 30 minutes. Blood will be drawn in each position to measure hormones that regulate blood pressure and blood volume. An additional sample will be collected in the supine position for the autoantibody assessment.

  • 24-hour heart rhythm and blood pressure monitoringProcedure

    Blood pressure, heart rate and ECG monitoring for 24 hours

  • Quantitative Axonal Sudomotor Reflex TestingProcedure

    The QSART assesses the ability of sympathetic nerve terminals in the skin to release acetylcholine and increase sweat production. The test is performed at 4 sites over the forearm, proximal lateral leg, medial distal leg and proximal foot.

  • Autonomic function testsProcedure

    The autonomic function tests will determine how well the autonomic nervous system regulates blood pressure and heart rate. These tests include breathing deeply for two minutes, breathing fast for 30 seconds, maintaining a handgrip for 3 minutes, breathing against pressure for 15 seconds, and placing the hand in ice water for 1 minute. In addition, participants will be tilted up on a tilt table for up to 10 minutes while recording their heart rate, blood pressure and cardiac output.

  • Rebreathing testOther

    Cardiac output will be measured using the rebreathing technique (Innocor)

  • Assessment of splanchnic capacitanceOther

    Splanchnic capacitance will be assessed using cpap and body impedance to construct pressure volume curves

  • microneurographyProcedure

    microneurography will be measured in the peroneal nerve to assess sympathetic activity.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Autoantibody levelsTime frame: up to 10 minutes
  2. Blood pressure after phenylephrine bolusesTime frame: 1-2 minutes after bolus injections
  3. Heart rate after isoproterenol bolusesTime frame: 1-2 minutes after bolus injections
  4. Orthostatic change in heart rateTime frame: up to 10 minutes

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma

  • Autonomic Dysfunction Center

    Nashville, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.